MA43342A - Compositions et procédé d'inhibition de cellules souches cancéreuses - Google Patents

Compositions et procédé d'inhibition de cellules souches cancéreuses

Info

Publication number
MA43342A
MA43342A MA43342A MA43342A MA43342A MA 43342 A MA43342 A MA 43342A MA 43342 A MA43342 A MA 43342A MA 43342 A MA43342 A MA 43342A MA 43342 A MA43342 A MA 43342A
Authority
MA
Morocco
Prior art keywords
compositions
stem cells
cancery
inhibition
csc
Prior art date
Application number
MA43342A
Other languages
English (en)
Inventor
Elaine M Hurt
Sotirios Karathanasis
Ralph Minter
Steven Rust
Alan Sandercock
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA43342A publication Critical patent/MA43342A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • C12N5/0695Stem cells; Progenitor cells; Precursor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)

Abstract

La présente invention concerne généralement des compositions et des procédés utiles dans le traitement du cancer. Plus spécifiquement, les procédés et les compositions peuvent être utilisés pour détecter, quantifier, inhiber, tuer, différencier ou éliminer les cellules souches cancéreuses (csc) et peuvent être utilisés dans le traitement des cancers associés aux csc, en particulier les cancers et les csc qui expriment lox1. .
MA43342A 2015-09-30 Compositions et procédé d'inhibition de cellules souches cancéreuses MA43342A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562235144P 2015-09-30 2015-09-30

Publications (1)

Publication Number Publication Date
MA43342A true MA43342A (fr) 2018-08-08

Family

ID=57121217

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43342A MA43342A (fr) 2015-09-30 Compositions et procédé d'inhibition de cellules souches cancéreuses

Country Status (13)

Country Link
US (2) US11192948B2 (fr)
EP (1) EP3356414A1 (fr)
JP (1) JP6938478B2 (fr)
KR (1) KR20180054818A (fr)
CN (1) CN108290952B (fr)
AU (2) AU2016329409B2 (fr)
CA (1) CA3000285A1 (fr)
HK (2) HK1255053A1 (fr)
IL (1) IL258242B2 (fr)
MA (1) MA43342A (fr)
RU (2) RU2752610C1 (fr)
SG (1) SG10202002926UA (fr)
WO (1) WO2017055511A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120474A1 (fr) * 2018-12-21 2020-06-25 23Andme, Inc. Anticorps anti-il-36 et leurs procedes d'utilisation
CN111303280B (zh) * 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP2591771A1 (fr) 2002-04-11 2013-05-15 MedImmune, LLC Conservation de matières bio-actives au moyen de mousse lyophilisée
US7258873B2 (en) 2002-04-11 2007-08-21 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
CA2508592A1 (fr) 2002-12-17 2004-07-15 Medimmune Vaccines, Inc. Pulverisation haute pression de materiaux bioactifs
JP2006022063A (ja) 2004-07-09 2006-01-26 Univ Nihon Lox−1遺伝子発現抑制剤
US8481314B2 (en) 2007-02-23 2013-07-09 Baylor Research Institute Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)
US20090311271A1 (en) * 2008-05-29 2009-12-17 Wyeth Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1)
WO2010138171A2 (fr) 2009-05-23 2010-12-02 Incube Labs, Llc Méthodes de traitement du cancer faisant appel à des cellules souches
US9778264B2 (en) * 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
WO2013119964A2 (fr) * 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification et enrichissement de sous-populations cellulaires
GB2503148A (en) 2011-02-24 2013-12-18 Vermillion Inc Biomarker panels diagnostic methods and test kits for ovarian cancer
JP2015526087A (ja) 2012-08-15 2015-09-10 ネオステム オンコロジー リミテッド ライビリティ カンパニー 高純度癌幹細胞及び高純度癌幹細胞集団の迅速な作製方法
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
CN113583130A (zh) 2014-10-01 2021-11-02 免疫医疗有限公司 对lox1具有特异性的结合蛋白及其用途

Also Published As

Publication number Publication date
AU2016329409A1 (en) 2018-05-10
CA3000285A1 (fr) 2017-04-06
JP6938478B2 (ja) 2021-09-22
RU2021120719A (ru) 2021-11-03
SG10202002926UA (en) 2020-05-28
US11192948B2 (en) 2021-12-07
IL258242B2 (en) 2023-02-01
US20180273616A1 (en) 2018-09-27
AU2016329409B2 (en) 2019-11-28
CN108290952A (zh) 2018-07-17
IL258242A (en) 2018-05-31
JP2018529716A (ja) 2018-10-11
CN108290952B (zh) 2023-05-02
WO2017055511A1 (fr) 2017-04-06
AU2020201276B2 (en) 2022-03-17
HK1257189A1 (zh) 2019-10-18
RU2752610C1 (ru) 2021-07-29
US20220195037A1 (en) 2022-06-23
EP3356414A1 (fr) 2018-08-08
IL258242B (en) 2022-10-01
AU2020201276A1 (en) 2020-03-12
KR20180054818A (ko) 2018-05-24
HK1255053A1 (zh) 2019-08-02

Similar Documents

Publication Publication Date Title
CY1122306T1 (el) Συνθεσεις που περιλαμβανουν bakthpiaka στελεχη
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MA43943A (fr) Compositions et procédés pour traiter des patients avec des cellules mutantes rtk
MX2022011546A (es) Composiciones y metodos para el agotamiento de celulas cd137+.
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
NZ720949A (en) Methods and compositions for treating aging-associated conditions
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
CL2017002774A1 (es) Secuencias de uricasa mejorada y métodos de tratamiento
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
EA201991455A1 (ru) Композиции и способы лечения дефицита альфа-1-антитрипсина
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.